This paper is only available as a PDF. To read, Please Download here.
The mechanism of action of diazoxide vas investigated in dogs. Immunoreactive insulin, glucose, and free fatty acids were determined in treated and control dogs following intravenously administered glucose. The slower disappearance of glucose in the treated animals was associated with almost complete IRI suppression. Alpha adrenergic receptor blockade with phentolamine prevented the diabetogenic and insulin suppressive effects of diazoxide. Experiments in fasting dogs demonstrated that the elevation of FFA which follows diazoxide administration can be largely inhibited by beta adrenergic blockade with propranolol. The metabolic effects of diazoxide are therefore mediated either directly or indirectly through alpha and beta adrenergic receptors. Additional experiments indicated that the diazoxide effect on glucose tolerance and insulin secretion is not blocked by pretreatment with reserpine. Treatment with the massive doses of reserpine necessary to deplete tissue catecholamines caused a near-moribund state. However, the diazoxide effect could be demonstrated in the reserpinized animals that maintained the ability to secrete insulin normally in response to a glucose load. Our findings suggest that diazoxide stimulates alpha and beta adrenergic receptors directly.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Translational Research
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Clinical use of diazoxide and mechanism for its hyperglycemic effects.Diabetes. 1966; 15: 143
- Benzothiadiazine suppression of insulin release from normal and abnormal islet tissue in man.J. Clin. Invest. 1966; 45: 481
- Effects of different benzothiadiazines and catecholamines on insulin secretion.in: Forty-eighth Meet. Endocrine Soc. 1966: 78 (Abst.)
- Mechanisms for the regulation of serum insulin levels by catecholamines in man.J. Clin. Invest. 1966; 45: 1057
- The photometric microdetermination of blood glucose with glucose oxidase.J. Lab. & Clin. Med. 1958; 51: 448
- Titration of free fatty acids of plasma: A study of current methods and a new modification.J. Lipid Res. 1960; 1: 199
- A radioimmunological assay method for insulin using insulin-I125 and gel filtration.J. Clin. Endocrinol. 1965; 25: 1043
- Interpretation of the rapid intravenous glucose tolerance test in normal individuals and in mild diabetes mellitus.J. Clin. Invest. 1953; 32: 428
- The release of norepinephrine from the mammalian heart by reserpine.J. Pharmacol. & Exper. Therap. 1958; 123: 153
- Studies on diazoxide hyperglycemia.Diabetes. 1964; 13: 639
- The effect of diazoxide of chlorothiozide on glucose uptake in vitro.Metabolism. 1966; 15: 88
- The acute hemodynamic effect of diazoxide in man.Circulation. 1963; 28: 89
- Effects of diazoxide on insulin secretion in vitro.Lancet. 1966; 1: 128
- Regulation of insulin secretion studied with pieces of rabbit pancreas incubated in vitro.Biochem. J. 1964; 93: 66
- Some factors modifying the action of hormones on glucose uptake by adipose tissue in vitro.Endocrinology. 1962; 70: 420
- Effect of guanethidine and adrenal demedullation in hyperglycemic responses to diazoxide in rats.in: ed. 3. Proc. Soc. Exper. Biol. & Med. 117. 1964: 572
- The effect of a benzothiadiazine, diazoxide on carbohydrate metabolism.Diabetes. 1964; 13: 408
- Further studies on the metabolic effects of diazoxide.J. Pharmacol. & Exper. Therap. 1965; 150: 455
- Biochemische Grundlagen der Diazoxide-Hyperglykamie.Arch. exper. Path. u. Pharmakol. 1966; 253: 372
Accepted: January 20, 1967
Received: November 15, 1966
☆Supported by Research Grant AM 10151-01, National Institute of Arthritis and Metabolic Diseases, United States Public Health Service.
© 1967 Published by Elsevier Inc.